FDA puts par­tial hold on Gilead’s CD47 hope­ful in AML

The FDA put a par­tial clin­i­cal hold on Gilead’s ma­grolimab for acute myeloid leukemia, a month af­ter the com­pa­ny scrapped late-stage de­vel­op­ment of the CD47 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA